HCG in plain English — what LH mimicry actually does
4 min read · Uplevel editorial
In 1927, two scientists named Selmar Aschheim and Bernhard Zondek discovered that injecting urine from pregnant women into immature female mice caused ovarian development — something that shouldn't have happened in animals that hadn't yet reached sexual maturity. They had stumbled onto evidence of a powerful hormonal signal being excreted in pregnancy urine in large quantities. That signal turned out to be human chorionic gonadotropin, and for decades it was extracted from the urine of pregnant women and used as a pharmaceutical. The fact that it worked — and kept working across a remarkable range of clinical applications — suggested something important about its mechanism. HCG was not mimicking a signal that existed only in pregnancy. It was speaking a language the body's own endocrine receptors already understood fluently.
That language is LH. Luteinizing hormone. And understanding why HCG speaks it so well requires a brief detour into protein structure.
Gonadotropins are a family of glycoprotein hormones — hormones built from protein chains with sugar molecules attached — that includes LH, FSH, HCG, and TSH (thyroid-stimulating hormone). All four of them share an identical alpha subunit: the same protein chain, the same structure, the same amino acid sequence. What distinguishes them from each other is the beta subunit — a second protein chain that pairs with the alpha subunit to form the complete molecule. The beta subunit is what determines which receptor a gonadotropin binds to and what effect it produces. LH's beta subunit and HCG's beta subunit are structurally similar — about 80% identical in amino acid sequence — with HCG carrying an additional extension at the C-terminal end of its beta chain that LH doesn't have.
That C-terminal extension is the key to HCG's pharmacological personality. It makes HCG substantially more resistant to metabolic degradation. LH, after being released by the pituitary, has a serum half-life of roughly 20 to 30 minutes — it's cleared quickly because pulsatile signaling is the point. The LH receptor in the gonads is designed to respond to peaks and troughs, not a constant tonic signal. HCG, with its extended beta tail, resists the enzymatic cleavage that eliminates LH so quickly. Its half-life in circulation is roughly 24 to 36 hours, depending on formulation and individual metabolism — orders of magnitude longer. This is why HCG can be dosed once or twice or three times per week and still maintain meaningful LH-receptor activation, while recapitulating the LH signal in a way that the pituitary's own output never could at that frequency.
The LH receptor itself sits on three primary cell types in the reproductive system: Leydig cells in the testes, theca cells in the ovarian follicle, and luteal cells in the corpus luteum. In men, Leydig cell activation drives testosterone synthesis — the conversion of cholesterol through a series of enzymatic steps to testosterone, which then moves into the interstitial fluid of the testis at concentrations roughly a thousand times higher than serum, providing the androgen-rich environment necessary for spermatogenesis. In women, theca cell activation produces androstenedione and other androgen precursors that the granulosa cells then convert to estradiol. In the corpus luteum — the structure left behind after ovulation — LH receptor activation sustains progesterone output and keeps the uterine lining prepared for implantation.
HCG does all three of these things, through the same receptor, with the same downstream signaling cascade. The Leydig cell, the theca cell, the luteal cell — none of them can reliably distinguish HCG from LH at the receptor level. This is the exploit. This is what makes HCG clinically useful across applications that look, on the surface, quite different from each other.
In male hypogonadotropic hypogonadism — a condition where the pituitary produces insufficient LH, usually due to a structural, genetic, or acquired defect — HCG provides direct testicular stimulation that the pituitary can't. Rather than trying to repair the pituitary-hypothalamic axis, HCG goes straight to the Leydig cell and tells it to work. Men with hypogonadotropic hypogonadism on HCG therapy can achieve normal serum testosterone, maintained or restored testicular volume, and in many cases functional spermatogenesis — outcomes that testosterone replacement alone cannot produce, because testosterone replacement further suppresses the axis without addressing the downstream goal.
In ovulation induction — one of the foundational tools of assisted reproduction — HCG is used to trigger the final maturation of a dominant follicle and release of the oocyte. Follicles are grown and matured using FSH stimulation over a period of days; then a bolus injection of HCG mimics the LH surge that would naturally trigger ovulation. The follicle responds with resumption of meiosis, the oocyte completes its first meiotic division, and ovulation follows approximately 36 to 40 hours after the injection. The timing precision this enables is what makes egg retrieval for IVF possible — you know when the oocyte will be ready. Without a reliable LH surge equivalent, that window would be unpredictable and collection would fail far more often.
In TRT as an adjunct, as covered elsewhere in more detail, HCG performs the job of a stand-in pituitary: delivering the LH signal to the testes while the real pituitary is suppressed by exogenous testosterone's negative feedback on the hypothalamic-pituitary axis. The testes respond as they would to endogenous LH. Intratesticular testosterone is maintained. Spermatogenesis continues. Testicular atrophy is prevented or minimized.
The dose-response relationship is where context becomes everything: the same molecule does very different jobs depending on the dose. A maintenance dose of 250 to 500 IU two to three times weekly is enough to keep Leydig cells active and testicular volume preserved, while the 5,000 to 10,000 IU bolus used to trigger ovulation is a different order of signal entirely — and through all of it, HCG's minimal FSH activity remains the consistent limit on what LH mimicry alone can accomplish. Matching the molecule to a specific goal at a specific dose is therefore the whole game, and it is the kind of decision that belongs with a prescribing provider rather than a generic protocol.
Frequently asked